STI571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: Validating the promise of molecularly targeted therapy

Michael J. Mauro, Michael E. O'Dwyer, Brian J. Druker

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

The deregulated tyrosine kinase activity of the Bcr-Abl fusion protein has been established as the causative molecular event in chronic myelogenous leukemia (CML). Thus the Bcr-Abl tyrosine kinase is an ideal target for pharmacologic inhibition. STI571 (formerly CGP57148B), is an Abl-specific tyrosine kinase inhibitor that in preclinical studies selectively kills Bcr-Abl-containing cells in vitro and in vivo. The results of clinical studies have demonstrated the potential of molecularly targeted therapies, and STI571 is emerging as a new therapeutic agent for CML.

Original languageEnglish (US)
Pages (from-to)S77-S78
JournalCancer Chemotherapy and Pharmacology
Volume48
Issue numberSUPPL. 1
DOIs
StatePublished - Dec 1 2001

Keywords

  • Bcr-Abl
  • Chronic myelogenous leukemia
  • ST1571
  • Targeted therapy
  • Tyrosine kinase

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'STI571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: Validating the promise of molecularly targeted therapy'. Together they form a unique fingerprint.

Cite this